MDT
NYSEMedtronic plc.
SectorHealth CareIndustryBiotechnology: Electromedical & Electrotherapeutic Apparatus
Website
News25/Ratings12
News · 26 weeks67-58%
2025-10-262026-04-19
Mix3490d
- Other17(50%)
- Insider5(15%)
- Analyst4(12%)
- SEC Filings3(9%)
- Offering3(9%)
- Dividends2(6%)
Latest news
25 items- PROrchestra BioMed to Present AVIM Therapy Clinical and Mechanistic Data at HRS 2026Pre-randomization Atrioventricular Interval Modulation Therapy ("AVIM Therapy") set-up data from the MODERATO II randomized, prospective, multi-center, double-blind, controlled trial show an immediate average reduction of 13.2 mmHg in office systolic blood pressure ("oSBP")97% of patients experienced an immediate blood pressure reduction of >5 mmHg reduction in oSBP prior to randomizationAVIM Therapy demonstrated the potential to deliver immediate, substantial, and sustained reductions in blood pressure, with evidence of improved diastolic function and reverse cardiac remodelingThe BACKBEAT Global Pivotal Trial, which Orchestra BioMed is actively enrolling as part of a strategic collaboratio
- PRMedtronic completes acquisition of CathWorks, expanding its leadership in transforming care for patients with cardiovascular diseaseCathWorks FFRangio® System employs drug-free, wire-free technology for comprehensive physiological assessmentGALWAY, Ireland, April 20, 2026 /PRNewswire/ -- Medtronic plc (NYSE:MDT), a global leader in healthcare technology, today announced it has completed its acquisition of CathWorks, a privately held medical device company, which aims to transform how coronary artery disease (CAD) is diagnosed and treated. The acquisition follows a 2022 strategic partnership with a co-promotion agreement for the CathWorks FFRangio® System where it is commercially available in the U.S., Europe and Japan. The acquisition is valued at $585 million with potential undisclosed earn-out payments post-acquisition
- PRThe Infrastructure Play Hiding in Plain Sight Across Cardiac CareVANCOUVER, British Columbia, April 16, 2026 (GLOBE NEWSWIRE) -- Equity-Insider.com News Commentary – The American heart care market is undergoing a structural shift that most retail investors haven't noticed yet. The U.S. cardiovascular devices sector is on track to nearly double, from $22.08 billion in 2025 to $41.29 billion by 2032, fueled by aging demographics and a wave of next-generation diagnostic platforms[1]. At the same time, 75% of U.S. health systems are now rolling out AI-powered clinical tools, with cardiac imaging and documentation leading the charge[2]. That convergence of hardware growth and software integration is creating asymmetric upside for companies building the infra
- PRMedtronic to announce financial results for its fourth quarter and full fiscal year 2026GALWAY, Ireland, April 13, 2026 /PRNewswire/ -- Medtronic plc (NYSE:MDT), a global leader in healthcare technology, today announced that it will report financial results on Wednesday, June 3, 2026, for its fourth quarter and full fiscal year 2026, which ends on Friday, April 24, 2026.A news release containing summary financial information will be issued at 5:45 a.m. Central Time (CT) and will be available at https://news.medtronic.comA video webcast to discuss results will begin at 6:45 a.m. CT and can be accessed at https://investorrelations.medtronic.comWithin 24 hours of the video webcast, a replay and transcript of the prepared remarks will be available by clicking on the Events link at
- PRTelix Strengthens Board with Additional Director AppointmentsMELBOURNE, Australia and INDIANAPOLIS, April 09, 2026 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ:TLX, "Telix") today announces two additional Non-Executive Director (NED) appointments, effective May 11, 20261, as part of Board expansion and succession planning: Maria Rivas, MD is an experienced public company board director and S&P 100 senior pharmaceutical executive with more than 25 years' experience in late-stage clinical development, commercialization and governance leadership. Dr. Rivas currently serves on the board of directors of The Cooper Companies, Inc. (NASDAQ:COO), a medical technology company, and also served as an independent director for Medidata
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Medtronic plc.SCHEDULE 13G/A - Medtronic plc (0001613103) (Subject)
- PRMedtronic Receives FDA Clearance for Stealth AXiS™ Surgical System for Cranial and ENT ProceduresGALWAY, Ireland, March 27, 2026 /PRNewswire/ -- Medtronic (NYSE:MDT), a global leader in healthcare technology, today announced U.S. Food and Drug Administration (FDA) clearance of the Stealth AXiS™ surgical system for cranial and ear, nose, and throat (ENT) procedures. Cleared for spine procedures in February, the Stealth AXiS™ surgical system unifies surgical planning, navigation, and robotics into a single intelligent system to support surgeons with greater precision and real-time insights during complex procedures. This clearance reinforces Medtronic's strategy to deliver connected technologies that support surgeons across multiple specialties on a single platform."Cranial procedures req
- SECMedtronic plc. filed SEC Form 8-K: Regulation FD Disclosure8-K - Medtronic plc (0001613103) (Filer)
- PRMedtronic OmniaSecure™ defibrillation lead is the first lead of its kind to receive FDA approval for conduction system pacingBuilt for high reliability, world's only lumenless defibrillation lead approved for placement in the left bundle branch area GALWAY, Ireland, March 23, 2026 /PRNewswire/ -- Medtronic plc (NYSE:MDT), a global leader in healthcare technology, received U.S. Food and Drug Administration (FDA) approval for an expanded indication for the OmniaSecure™ defibrillation lead. Now approved for placement in the left bundle branch (LBB) area, the lead can be used for conduction system pacing (CSP), which closely mimics the heart's natural physiology. Additionally, patients in need of cardiac resynchronization may benefit from left bundle branch optimized cardiac resynchronization therapy (LOT-CRT), a nove
- PROrchestra BioMed Reports Full Year 2025 Financial Results and Provides Fourth Quarter Business Update$106.5 million cash position as of December 31, 2025 to be further enhanced by $35 million expected from Medtronic and Ligand in Q2 2026 from previously announced transactions, as well as Haemonetics' Vivasure acquisition proceeds$33.5 million in 2025 non-recurring revenue primarily driven by impact of new Virtue SAB agreement with Terumo that was announced in October 2025Strong balance sheet supports focused execution of pivotal trials for both AVIM Therapy and Virtue SAB programs NEW HOPE, Pa., March 12, 2026 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (NASDAQ:OBIO) ("Orchestra BioMed" or the "Company"), a biomedical company accelerating high-impact technologies to patients thro
- PRMedtronic to acquire Scientia Vascular, marrying access and therapeutic portfolios for neurovascular careDeal complements Medtronic's Neurovascular portfolio, delivering simplicity and access when 'time is brain'GALWAY, Ireland, March 10, 2026 /PRNewswire/ -- Medtronic today announced its entry into a definitive agreement to acquire Scientia Vascular, a company with critical, innovative technology across the neurovascular portfolio. The acquisition is valued at $550 million, subject to customary adjustments, with potential undisclosed earn-out and milestone payments post-acquisition.Scientia is a private company operating in Salt Lake City, Utah, with approximately 310 employees. Under founder and current chief technology officer John Lippert, the company has developed best-in-class access prod
- PRMiniMed to begin trading on Nasdaq Global Select MarketGALWAY, Ireland, March 6, 2026 /PRNewswire/ -- Medtronic plc (NYSE:MDT), a global leader in healthcare technology, announced that MiniMed Group, Inc. (NASDAQ:MMED) will begin trading today on the Nasdaq Global Select Market (Nasdaq) under the ticker symbol "MMED" in connection with its initial public offering ("IPO")."Today marks an exciting milestone for both MiniMed and Medtronic. Despite a challenging market backdrop shaped by geopolitical uncertainty, the teams successfully executed an oversubscribed offering and the second largest IPO in Medtech history," said Geoff Martha, Medtronic chairman and chief executive officer. "Establishing MiniMed as a standalone entity positions the company
- INSIDERNew insider Medtronic Plc claimed ownership of 252,813,348 shares (SEC Form 3)3 - Medtronic plc (0001613103) (Reporting)
- PRMiniMed announces pricing of initial public offeringGALWAY, Ireland and NORTHRIDGE, Calif., March 5, 2026 /PRNewswire/ -- MiniMed Group, Inc. (MiniMed), a subsidiary of Medtronic plc (Medtronic) (NYSE:MDT), today announced the pricing of its initial public offering (IPO) of 28,000,000 shares of its common stock at a price to the public of $20.00 per share. The shares are expected to begin trading on the Nasdaq Global Select Market (Nasdaq) on March 6, 2026, under the symbol "MMED." The offering is expected to close on March 9, 2026, subject to customary closing conditions. MiniMed has granted the underwriters a 30-day option to p
- INSIDEREVP & Chief Financial Officer Pieton Thierry covered exercise/tax liability with 2,976 units of Ordinary Shares, decreasing direct ownership by 7% to 37,574 units (SEC Form 4)4 - Medtronic plc (0001613103) (Issuer)
- PRMedtronic announces cash dividend for fourth quarter of fiscal year 2026GALWAY, Ireland, March 5, 2026 /PRNewswire/ -- The board of directors of Medtronic plc (NYSE:MDT) on Thursday, March 5, 2026, approved the company's cash dividend for the fourth quarter of fiscal year 2026 of $0.71 per ordinary share. This quarterly declaration is consistent with the dividend increase announcement made by the company in May 2025. Medtronic is a constituent of the S&P 500 Dividend Aristocrats index, having increased its annual dividend payment for the past 48 consecutive years. The dividend is payable on April 17, 2026, to shareholders of record at the close of business on March 27, 2026.About MedtronicBold thinking. Bolder actions. We are Medtronic. Medtronic plc, headquarte
- PRMedtronic CFO Thierry Piéton to speak at upcoming investor conferencesGALWAY, Ireland, March 3, 2026 /PRNewswire/ -- Medtronic plc (NYSE:MDT), a global leader in healthcare technology, today announced that Thierry Piéton, Medtronic executive vice president and chief financial officer, will participate in fireside chats at the following investor conferences:Barclays 28th Annual Global Healthcare ConferenceTuesday, March 10, 2026, at 10:30 a.m. a.m. EST (9:30a.m. CST)Leerink Partners Global Healthcare ConferenceWednesday, March 11, 2026 at 9:20 a.m. EST (8:20 a.m. CST).A live webcast for each session will be available on the date and time of each of the conferences noted above by clicking on the Investors Events link at: http://investorrelations.medtronic.com. A
- INSIDEREVP & President Cardiovascular Kiil Harry Skip exercised 50,876 units of Ordinary Shares at a strike of $90.90 and sold $5,132,217 worth of Ordinary Shares (52,524 units at $97.71), decreasing direct ownership by 5% to 32,768 units (SEC Form 4)4 - Medtronic plc (0001613103) (Issuer)
- PRMedtronic begins EMEA commercial launch of MiniMed Go Smart MDI system with Simplera sensorReal-time actionable insights on one mobile app for people who manage their diabetes using multiple daily injectionsGALWAY, Ireland, Feb. 25, 2026 /PRNewswire/ -- Medtronic (NYSE:MDT), a global leader in healthcare technology, today announced the commercial launch in Europe of the MiniMed Go™ Smart MDI system with the Simplera™ sensor. The system, which is the first and only solution to integrate data from the InPen™ smart insulin pen and the Simplera™ sensor into a single mobile app, is designed to help people who use multiple daily injections (MDI) to better control their diabetes. The launch will be rolled out gradually across Europe starting this month.
- INSIDERChief Accounting Officer Blomquist Denise L. gifted 340 units of Ordinary Shares, decreasing direct ownership by 3% to 11,966 units (SEC Form 4)4 - Medtronic plc (0001613103) (Issuer)
- SECSEC Form 10-Q filed by Medtronic plc.10-Q - Medtronic plc (0001613103) (Filer)
- PRMiniMed announces launch of IPO roadshowGALWAY, Ireland, Feb. 24, 2026 /PRNewswire/ -- MiniMed Group, Inc. (MiniMed), a subsidiary of Medtronic plc (Medtronic) (NYSE:MDT), today announced that it has launched a roadshow for the initial public offering (IPO) of 28,000,000 shares of its common stock. The proposed offering is part of Medtronic's previously announced plan to separate its Diabetes business into an independent public company.The IPO price is currently expected to be between $25.00 and $28.00 per share. The underwriters will also be granted a 30-day option to purchase up to an additional 4,200,000 shares at the IPO price, less underwriting discounts and commissions. MiniMed expects to list its common stock on the Nasdaq
- SECMedtronic plc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Medtronic plc (0001613103) (Filer)
- PRMedtronic reports strong third quarter fiscal 2026 results with highest enterprise revenue growth in 10 quartersCardiovascular portfolio up 11% year-over-year; Cardiac Ablation Solutions grew 80% on strength of pulsed field ablation portfolioGALWAY, Ireland, Feb. 17, 2026 /CNW/ -- Medtronic plc (NYSE:MDT), a global leader in healthcare technology, today announced financial results for its third quarter (Q3) of fiscal year 2026 (FY26), which ended January 23, 2026.Q3 Key HighlightsRevenue of $9.0 billion, increased 8.7% as reported and 6.0% organic, 50 basis points ahead of Q3 guidanceGAAP diluted EPS of $0.89; non-GAAP diluted EPS of $1.36, three cents ahead of Q3 guidance mid-pointCompany reiterates FY26 organic revenue growth and EPS guidanceCardiac Ablation Solutions revenue increased 80%, includin
- PRMedtronic announces first surgery with Hugo™ robotic-assisted surgery system in the U.S. performed at Cleveland ClinicNewly FDA-cleared system helps expand patient access to minimally invasive surgeryCleveland Clinic joins nationally recognized academic medical centers including Atrium Health Wake Forest Baptist High Point Medical Center as first hospitals in the U.S. to install Hugo RAS systemGALWAY, Ireland, Feb. 17, 2026 /PRNewswire/ -- Medtronic today announced that the first U.S. commercial surgical case using its recently FDA-cleared Hugo™ robotic-assisted surgery (RAS) system has been successfully performed by Jihad Kaouk, MD, professor and chair of the Glickman Urologic Institute and the Zegarac-Pollock Endowed Chair in Robotic Surgery at Cleveland Clinic.Dr. Kaouk successfully completed a robotic-a